Acorda Therapeutics (ACOR) has acquired the rights in the Americas and certain other territories to two nerve pain treatments from NeurogesX (NGSX.OB) - FDA approved Qutenza and "Phase III ready" NP-1998. Acorda paid $8M up front and will pay as much as $5m in milestones related to NP-1998. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Fri, 12:02PM)
at Benzinga.com (Feb 12, 2015)
at Benzinga.com (Feb 11, 2015)
at Nasdaq.com (Jan 23, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs